(Q46965009)

26 December 2017

review article

1 reference

title

What has prevented the expansion of insulin sensitisers? (English)

1 reference

26 December 2017

1 reference

Jerry R Colca

1

1 reference

26 December 2017

Rolf F Kletzien

series ordinal

2

1 reference

26 December 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

26 December 2017

Expert Opinion on Investigational Drugs

published in

1 reference

26 December 2017

volume

15

1 reference

26 December 2017

issue

3

1 reference

26 December 2017

page(s)

205-210

1 reference

26 December 2017

PPAR gamma and the treatment of insulin resistance

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

New oral thiazolidinedione antidiabetic agents act as insulin sensitizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

PAT5A: A Partial Agonist of Peroxisome Proliferator-Activated Receptor γ Is a Potent Antidiabetic Thiazolidinedione Yet Weakly Adipogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

Effect of heterozygous PPARgamma deficiency and TZD treatment on insulin resistance associated with age and high-fat feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

Troglitazone action is independent of adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

Peroxisome proliferation-activated receptor (PPAR)gamma is not necessary for synthetic PPARgamma agonist inhibition of inducible nitric-oxide synthase and nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

Identification of a novel mitochondrial protein (“mitoNEET”) cross-linked specifically by a thiazolidinedione photoprobe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

Mitochondrial genome mutations in hypertensive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

Expression and characterization of recombinant rat Acyl-CoA synthetases 1, 4, and 5. Selective inhibition by triacsin C and thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.205

10.1517/13543784.15.3.205

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

16503758

1 reference

26 December 2017